

BEST AVAILABLE COPY

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 01662/54902	SERIAL NO. 10/045,510
	APPLICANT DOLITZKY et al.	
	FILING DATE October 19, 2001	GROUP 1621

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUB-CLASS	FILING DATE*
<i>SPB</i>	4,611,078	Sept. 9, 1986	Husbands et al.	—	—	

* - if pertinent

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
<i>SPB</i>	WO 00/32555	June 8, 2000	PCT			N/A	
<i>SPB</i>	WO 02/36542	May 10, 2002	PCT			N/A	
<i>SPB</i>	WO 02/46140	June 13, 2002	PCT			N/A	


OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.	
<i>SPB</i>	J.P. Yardley, et al., 2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine Derivatives: Synthesis and Antidepressant Activity, Journal of Medicinal Chemistry, 1990, 33, pp. 2899-2905	

EXAMINER	<i>JFB</i>	DATE CONSIDERED	<i>2/22/04</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

LAST AVAILABLE COPY

**SUPPLEMENTAL INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT**



ATTY. DOCKET NO.
01662/54902

SERIAL NO.
10/045,510

APPLICANT
DOLITZKY et al.

FILING DATE
October 19, 2001

GROUP
1621

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT & TRADEMARK OFFICE NUMBER	PATENT DATE	NAME	CLASS	SUB-CLASS	FILING DATE*

* - if pertinent

RECEIVED

AUG 06 2002

FOREIGN PATENT DOCUMENTS

TECH CENTER 1600/2900

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
<i>SG</i>	WO 02/36542 A1	May 10, 2002	PCT			<i>X</i>	<i>n/a</i>
<i>SG</i>	WO 02/46140A1	June 13, 2002	PCT			<i>X</i>	<i>n/a</i>

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.	

EXAMINER	<i>J. B.</i>	DATE CONSIDERED	<i>2/22/04</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 01662/54902	SERIAL NO. 10/045,510
	APPLICANT DOLITZKY et al.	
	FILING DATE October 19, 2001	GROUP 1621



U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUB-CLASS	FILING DATE

RECEIVED

- if pertinent

JUL 17 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
<i>SP</i>	Daniel Vega et al., 1-[2-(1-Hydroxycyclohexyl)-2-(4-methoxyphenyl)ethyl]dimethyl-ammonium chloride (venlafaxine hydrochloride), Acta Crystallographica Section C Crystal Structure Communications, 2000, C56, pp. 1009-1010

EXAMINER	DATE CONSIDERED
<i>TT Bod</i>	<i>2/20/04</i>

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**COPY OF PAPERS
ORIGINALLY FILED**

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**



ATTY. DOCKET NO.
01662/54902

SERIAL NO.
10/045,510

APPLICANT
DOLITZKY et al.

FILING DATE
October 19, 2001

GROUP
1621

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUB-CLASS	FILING DATE*
<i>JB</i>	4,535,186	August 13, 1985	Husbands et al.			

* - if pertinent

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
<i>JB</i>	EP 0 797 991 A1	October 1, 1997	EP				

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.		

EXAMINER	DATE CONSIDERED
<i>JB</i>	<i>2/22/04</i>

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.